Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
OBIOthis companyOrchestra BioMed Holdings, Inc.	$5.80	-3.74×	3.13×	5.92×	-3.5×	-202.6%	99.4%	-154.7%	-157.4%	-83.2%	-52.4%	-25.0%	0.25×	0.37×	-45.13×	6.45×	0.0%	3	-2.89	1	D+
AVTXAvalo Therapeutics, Inc.	$7.28	-3.11×	2.93×	4,125.96×	-2.96×	-86.5%	100.0%	-123601.7%	-132642.4%	-94.2%	-70.2%	-21.1%	0.03×	0.17×	0×	8.14×	0.0%	2	4.43	2	B-
CRBUCaribou Biosciences, Inc.	$0.43	-1×	1.22×	13.31×	-1.13×	-908.6%	67.3%	-1220.5%	-1327.4%	-121.2%	-89.8%	-75.7%	0.22×	-0.1×	0×	5.71×	0.0%	3	-7.25	2	C
ENTAEnanta Pharmaceuticals, Inc.	$11.42	-3.12×	3.95×	3.91×	-5.99×	-669.1%	93.0%	-130.7%	-125.4%	-126.5%	-31.4%	-12.6%	3.11×	-2.38×	-11.11×	4.21×	0.0%	3	-0.92	1	C-
IVVDInvivyd, Inc.	$0.59	-8.23×	1.76×	7.96×	-3.99×	1722.3%	93.0%	-104.0%	-98.2%	-21.7%	-22.8%	-13.7%	0.01×	4.45×	0×	7.24×	0.0%	1	-4.47	3	B
PRLDPrelude Therapeutics Incorporated	$3.81	-2.25×	3.25×	18.38×	-1.48×	-2.4%	85.9%	-861.3%	-819.6%	-145.0%	-114.8%	-25.3%	0.26×	0.18×	0×	1.99×	0.0%	4	-3.06	2	C
Peer median	—	-3.11×	2.93×	13.31×	-2.96×	-86.5%	93.0%	-861.3%	-819.6%	-121.2%	-70.2%	-21.1%	0.22×	0.17×	0×	5.71×	0.0%	3	-3.06	2	—